Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Illustration: Sarah Grillo/Axios
The Senate's drug pricing bill would likely be better for the pharmaceutical industry than either President Trump's agenda or House Speaker Nancy Pelosi's.
Between the lines: Industry opposes anything that would hurt its bottom line, but of those three proposals, the Senate's "is a positive tradeoff," analyst Ronny Gal of AllianceBernstein wrote to investors this week.
Between the lines: The Senate bill could take some political heat off the industry, while Pelosi's bill and Trump's proposal to tie Medicare's prices to international prices would make bigger changes to the actual system.
How it works: The international pricing index and Senate bill both only focus on Medicare, but would change different parts of Medicare.
- The international pricing index would lower prices for Medicare Part B drugs, which are things like chemotherapy and eye drugs that are administered in doctors' offices. Regeneron, Roche, Amgen and Bristol-Myers Squibb generate the most revenue from Medicare Part B and therefore are most invested in killing that proposal.
- The Senate bill would cap some prices for Medicare Part D drugs — the ones patients pick up from pharmacies. Celgene, Novo Nordisk, GlaxoSmithKline and AstraZeneca would feel the most pain to sales, according to Gal.
- Because the Senate bill proposes the most temperate changes, the industry will push for that as the main political vehicle while mitigating the damage to companies most exposed to Part D.
Both of those proposals pale in comparison to Pelosi's bill, which would limit prices in all insurance plans, including the most lucrative commercial business.
- Pelosi's bill would "be a fundamental change of business model for the drug industry," Gal wrote, and it's why pharmaceutical lobbyists and Senate Republicans have said it's a nonstarter.